Advanced engineering of Fibrous Non-steroidal anti-inflammatory drug (NSAID) films for buccal application using Electrohydrodynamic Atomisation
type: CreativeWork
description: The development of therapeutic dosage (e.g. pharmaceutical) systems is an ongoing process which, in recent times has incorporated several emerging disciplines and themes at timely intervals. While the concepts surrounding dosages have developed and evolved, many polymeric excipients remain as the preferred choice of materials over existing counterparts, serving functions as matrix materials, coatings and providing other specific functional properties (e.g. adhesion, controlled release and mechanical properties). Therefore, polymer is employed as a matrix carrier of materials or as active release performance modulating agents for polymeric based dosages. There have been, however, developments in the deployment of synthetic polymeric materials (e.g. polycaprolactone, poly lactic co-glycolic acid) when compared to naturally occurring materials (e.g. lactose, gelatin). Additionally, numerous techniques have been advanced further to novel engineering polymeric structures which provide materials in micrometer to nanometer scale range. Some of these structures enabling technologies include spray drying, super critical processing, microfluidics and even wet chemical methods. Recently maturing processes which is operational at the ambient environment is electrohydrodynamic (EHDA) engineering methods (ES and ESy). They have emerged as robust technologies offering potential to fabricate a plethora of generic structures directly into a fibrous polymer matrix system (e.g. particles, fibres, bubbles and pre-determined patterns) on a broad scale range. This research focuses on key developments using EHDA technology for the pharmaceutical and biomaterial remits when selecting synthetic and/or naturally occurring polymers as pharmaceutical (and therapeutic) excipients. EHDA was employed to engineer NSAID drugs in fibre film form for buccal delivery. EHDA was selected to develop fibre film of Indomethacin, Diclofenac Sodium, Ketoprofen, and Piroxicam in cooperation of PVP, Ethocel, M…
abstract: The development of therapeutic dosage (e.g. pharmaceutical) systems is an ongoing process which, in recent times has incorporated several emerging disciplines and themes at timely intervals. While the concepts surrounding dosages have developed and evolved, many polymeric excipients remain as the preferred choice of materials over existing counterparts, serving functions as matrix materials, coatings and providing other specific functional properties (e.g. adhesion, controlled release and mechanical properties). Therefore, polymer is employed as a matrix carrier of materials or as active release performance modulating agents for polymeric based dosages. There have been, however, developments in the deployment of synthetic polymeric materials (e.g. polycaprolactone, poly lactic co-glycolic acid) when compared to naturally occurring materials (e.g. lactose, gelatin). Additionally, numerous techniques have been advanced further to novel engineering polymeric structures which provide materials in micrometer to nanometer scale range. Some of these structures enabling technologies include spray drying, super critical processing, microfluidics and even wet chemical methods. Recently maturing processes which is operational at the ambient environment is electrohydrodynamic (EHDA) engineering methods (ES and ESy). They have emerged as robust technologies offering potential to fabricate a plethora of generic structures directly into a fibrous polymer matrix system (e.g. particles, fibres, bubbles and pre-determined patterns) on a broad scale range. This research focuses on key developments using EHDA technology for the pharmaceutical and biomaterial remits when selecting synthetic and/or naturally occurring polymers as pharmaceutical (and therapeutic) excipients. EHDA was employed to engineer NSAID drugs in fibre film form for buccal delivery. EHDA was selected to develop fibre film of Indomethacin, Diclofenac Sodium, Ketoprofen, and Piroxicam in cooperation of PVP, Ethocel, M…
author: Nazari, Kazem
license: https://dora.dmu.ac.uk/bitstreams/c0f74a59-82e2-4adb-b681-622e5aea1579/download
date published: 2018
date modified: 2026-07-24T06:18:51Z
provider: De Montfort University
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: De Montfort University